RMS oncogenesis relies on the expression of myogenic TFs [57], generating at least four identified CRCs in RMS tissue and cell lines: (i) a pan-RMS CRC defined by expression of MYOD1 and MYOG; (ii) a fusion-positive RMS (FP-RMS), which includes FOXO1 (SEs regulating PAX3-FOXO1 or PAX7-FOXO1) and MYCN; (iii) a fusion-negative RMS including PAX7 and the AP1 family of TFs; and (iv) a normal muscle-specific CRC with TFs expressing Nur77 and MEF2D [58,59]. The gene discussed is MEF2D; the disease is colorectal carcinoma.